Ahead of a critical vote to fuel Dallas’ homelessness response with $10 million, the debate over whether the city was ...
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemogl ...
Nuwellis (NUWE) announced the presentation of new real-world data from New York City’s Lenox Hill Hospital at the 2025 American Society of ...
Poster presentations highlight AI-driven CD histopathology grading technology; morbidity and financial burden of idiopathic multicentric CD (iMCD); ...
The Ph.D. program at Gallaudet University prepares scholars and practitioners to lead in the design, development, and ...
The original definition of the word “bias,” when it entered the English language in the 16th century, was a diagonal line, and specifically one that cut across the warp or weft of a woven fabric. It ...
“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...
Long-term 7-year follow-up data from the Portal extension trial support the port delivery system as an effective strategy to ...
The Medicare Payment Advisory Commission (MedPAC) is once again beating the drum for reducing Medicare payment rates for ...
Findings reinforce Nuwellis’ leadership in precision ultrafiltration for patients with acute kidney injury and fluid overload.
Rusfertide was generally well-tolerated through 52 Weeks of treatment. The most common treatment-emergent adverse events (AE) in rusfertide-treated patients were injection site reactions (47.4%), ...
BGB-16673 showed high overall response rates in relapsed/refractory CLL/SLL, with a notable 94.4% response at the 200-mg dose level. Safety analysis revealed that 95.6% of patients experienced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback